Test Price
2,800 AED✅ Home Collection Available
ICAM1 Gene – Cerebral Malaria Susceptibility Genetic Test | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Our ICAM1 genetic susceptibility test delivers 99.9% diagnostic sensitivity via next-generation sequencing in an ISO 9001:2015‑accredited facility (Cert: INT/EGQ/2509DA/3139). We offer hospital‑grade home collection across all Emirates with cold‑chain integrity, VIP mobile phlebotomy from 8 AM to 11 PM, and complimentary telephonic post‑test clinical guidance. Insurance pre‑approval is streamlined via WhatsApp at +971 54 548 8731. DHA Facility License: 1143. Corporate Lab: DNA Labs UAE.
Test Overview & Methodology
The ICAM1 Gene – Cerebral Malaria Susceptibility Genetic Test identifies variants in the intercellular adhesion molecule 1 gene linked to severe Plasmodium falciparum cerebral malaria. Using advanced next‑generation sequencing, this test empowers clinicians and at‑risk individuals with precise genetic risk stratification – essential for preventive medicine in malaria‑endemic travel zones.
| Feature | Our Test (NGS) | Closest Alternative (PCR‑only) |
|---|---|---|
| Analytical Method | Next‑Generation Sequencing with full ICAM1 gene coverage | Targeted PCR for selected SNPs |
| Diagnostic Precision | >99.9% sensitivity; detects novel variants | Limited to known polymorphisms; ~85% sensitivity |
| Turnaround Time | 3–4 Weeks (comprehensive bioinformatics) | 5–7 Days (focused report) |
| Clinical Utility | Full gene profiling for preventive medicine, travel medicine, and research | Preliminary risk indication only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) advises: “This genetic test identifies inherited susceptibility to cerebral malaria, not active infection. A positive ICAM1 variant indicates increased risk that should be interpreted alongside travel history, clinical evaluation, and exposure risk. Always consult your managing physician before making any changes to prophylaxis.”
Advisory: Medication & Safety Warning
Important Safety Notice
Do not discontinue or modify any prescribed antimalarial medication or prophylaxis without consulting your doctor. This test is for genetic risk assessment only and must be interpreted in a clinical context.
Exclusion Criteria & Emergency Red Flags
- Active fever or signs of cerebral malaria (seek emergency care immediately).
- Known allergy to phlebotomy materials or inability to provide blood sample.
- Individuals under 18 years without legal guardian consent (as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Genetic results must be interpreted by a certified healthcare professional – not for self‑diagnosis.
Patient FAQ & Clinical Guidance
1. How does this NGS test detect cerebral malaria susceptibility?
This test sequences the entire ICAM1 gene to identify high-risk variants linked to cerebral malaria, providing a definitive yes/no susceptibility profile within 3–4 weeks. Unlike standard PCR panels that target only a few SNPs, our NGS method captures all rare and novel mutations that may increase parasite sequestration in brain capillaries, delivering a >99.9% sensitivity.
2. Is home collection available and how is my data protected under UAE law?
Yes, our ISO‑certified mobile phlebotomists collect blood at your doorstep from 8 AM to 11 PM daily, preserving DNA integrity in validated cold‑chain containers. All genetic data is handled under UAE PDPL (Federal Decree-Law No. 45 of 2021), encrypted, and not shared with third parties without explicit consent. Health information use complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
3. What should I do after receiving a positive susceptibility result?
A positive ICAM1 variant report indicates increased genetic risk; you should schedule a tele‑guidance session with our DHA‑licensed geneticist, who will explain prophylaxis options and refer you to a specialist. Always continue antimalarial medication as prescribed and never self‑diagnose cerebral malaria based solely on this result.
UAE Regulatory & Data Privacy Adherence
This test and its associated data handling fully comply with: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for genetic privacy, Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for electronic health records, and Federal Decree-Law No. 4 of 2016 on Medical Liability for patient consent and safety protocols. All genetic results are encrypted and accessible only to authorized healthcare professionals.
Clinical & Logistical Metadata
| Test Name | ICAM1 Gene – Cerebral Malaria Susceptibility Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood (VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS), Full Gene Coverage |
| ICD-10-CM Code | Z13.79 |
| LOINC Code | 91872-4 |
| DHA Facility License & Laboratory Address | License No. 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians